Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has ...

EDINBURGH, Scotland, January 14, 2025--(BUSINESS WIRE)--Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the ...

PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...

Pheno Therapeutics Ltd. has received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its lead candidate, PTD-802. The program will ...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has ...

Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis EDINBURGH, Scotland, January 14, 2025--(BUSINESS WIRE)--Pheno Therapeutics Limited., a ...

UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis Pheno Therapeutics ...